BioSpace News Archive

Nascent Biotech, Inc. (OTCQB:NBIO) a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that patients have been enrolled and initial dosing has begun in the Companys landmark Phase I trial to evaluate Pritumumab

B. Braun Interventional Systems Inc. (BIS) announced today that they will collaborate with Infraredx, a Nipro Company, to accelerate the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial for the B. Braun SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter, which received FDA Breakthrough Device Designation in late 2019

Brain Scientific Inc. (OTCQB: BRSF) (the “Company”), a neurology focused medical device and software company, has announced it has received its first purchase order for its NeuroCap™, a pre-gelled, disposable EEG headset, from the Department of Veterans Affairs – VA Medical Centers for one of its hospitals.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the publication in Scientific Reports of a paper entitled “A Novel Proteomics Approach to Epigenetic Profiling of Circulating Nucleosomes”.

TORONTO, March 31, 2021 /PRNewswire/ - Kontrol Technologies Corp. is pleased to provide an update on its manufacturing capacity as it relates to various milestones for the Ontario Together Fund.

Delic Holdings Inc. (the “Company”), (“DELIC”) (CSE: DELC) (OTCQB: DELCF), a psychedelic focused wellness company, is pleased to announce that its acquisition target, Complex Biotech Discovery Ventures Ltd.

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 6, 2021. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2021 financial results and respond to questions from financial analysts during the call.

PLEASANTON, Calif., March 31, 2021 Surface Ophthalmics, Inc., a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases, announced the appointment of Preeya K. Gupta, MD as Chief Medical Advisor.

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), today announced the signing of an agreement under which Immunic will settle its remaining obligation of a 4.4% royalty on net sales of selective oral DHODH inhibitor, IMU-838, for $17.25 million

Evive Biotech, a global biologics company developing novel biologic therapies, today announced the submission of its Biologics License Application (BLA) for Ryzneuta™ (also known as F-627) to the US Food & Drug Administration (FDA